InsiderTrades

Form 4 for XENE Xenon Pharmaceuticals Inc.

Accepted 2025-01-27 00:00:00 ET · period of report 2025-01-23 · accession 0000950170-25-009388 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2025-01-27 2025-01-23+ XENE MORTIMER IAN Pres, CEO, Dir M - OptEx $17.76 +55.0K 46.5K New +$976.8K
DMT 2025-01-27 2025-01-23+ XENE MORTIMER IAN Pres, CEO, Dir S - Sale+OE $40.25 -55.0K 31.3K -64% -$2.21M
DMT 2025-01-27 2025-01-23+ XENE MORTIMER IAN Pres, CEO, Dir M - OptEx $0.00 -55.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares 2025-01-27 M A 1,149 $17.76 32,451 D — —
2 Common Common Shares 2025-01-27 S D 15,166 $40.46 31,302 D — — (F4) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
3 Common Common Shares 2025-01-23 M A 16,217 $17.76 47,519 D — —
4 Common Common Shares 2025-01-23 S D 16,217 $40.08 31,302 D — — (F2) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
5 Common Common Shares 2025-01-24 M A 22,468 $17.76 53,770 D — —
6 Common Common Shares 2025-01-27 S D 1,149 $41.07 31,302 D — — (F5) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $41.01 to $41.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
7 Common Common Shares 2025-01-27 M A 15,166 $17.76 46,468 D — —
8 Common Common Shares 2025-01-24 S D 22,468 $40.20 31,302 D — — (F3) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.535, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
9 Derivative Stock Option (Right to Buy) 2025-01-24 M D 22,468 $0.00 16,315 D $17.76 · — to 2025-03-16 22,468 Common Shares (F6) The shares subject to the option are fully vested and exercisable.
10 Derivative Stock Option (Right to Buy) 2025-01-23 M D 16,217 $0.00 38,783 D $17.76 · — to 2025-03-16 16,217 Common Shares (F6) The shares subject to the option are fully vested and exercisable.
11 Derivative Stock Option (Right to Buy) 2025-01-27 M D 16,315 $0.00 0 D $17.76 · — to 2025-03-16 16,315 Common Shares (F6) The shares subject to the option are fully vested and exercisable.